Meeting
2016 ASCO Annual Meeting
Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.
Authors
Michael William Lattanzi
New York University School of Medicine, New York, NY
Michael William Lattanzi , Joseph Han , Una Moran , Kiersten Utter , Jeremy Tchack , Rachel Lubong Sabado , Nina Bhardwaj , Iman Osman , Anna C. Pavlick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3084)
DOI
10.1200/JCO.2016.34.15_suppl.3084
Abstract #
3084
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
First Author: Nina Bhardwaj
Poster
2014 ASCO Annual Meeting
Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
First Author: Jonathan S. Cebon
Poster
2014 ASCO Annual Meeting
Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.
First Author: Rachel Lubong Sabado
Poster
2014 ASCO Annual Meeting
Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.
First Author: Rachel Lubong Sabado